Roche Reports Result of Tecentriq (atezolizumab) + Platinum-Based CT in P-III IMvigor130 Study for Advanced Bladder Cancer

 Roche Reports Result of Tecentriq (atezolizumab) + Platinum-Based CT in P-III IMvigor130 Study for Advanced Bladder Cancer

Roche Reports Result of Tecentriq (atezolizumab) + Platinum Based CT in P-III IMvigor130 Study for Advanced Bladder Cancer

Shots:

  • involves assessing of Tecentriq + CT vs CT as monothx. in 1,213 patients with previously untreated LA or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy
  • The P-III IMvigor130 study results: mPFS (8.2 vs 6.3mos.); median OS (16.0 vs 13.4 mos.); ORR (47.4% vs 43.8%); safety data of combination therapy is consistent with the safety profile of Tecentriq with no new safety signals
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1receptors, currently being evaluated in 4 P-III studies in combination with other therapies for early and advanced bladder cancer

Click here to­ read full press release/ article | Ref: Roche | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post